Actinic Keratosis Market Revenue Opportunies By Key Vendors DUSA Pharmaceuticals, Inc., Tolmar Pharmaceuticals, Inc., Perrigo Company plc, Valeant Pharmaceuticals International

The treatment of actinic keratosis as a part of preventive strategy for the reduction of interrelated disorders, such as non-melanoma skin cancer, squamous cell carcinoma, and basal cell carcinoma is coming to the forefront. According to the U.S. National Library of Medicine, 2015, approximately 60% of squamous cell carcinomas of the skin probably arise from actinic keratosis. Therefore, the rising incidences of skin cancers, such as intra epidermal squamous cell carcinoma, invasive cutaneous squamous cell carcinoma, basal cell carcinoma, and melanoma is expected to augment the market growth. Moreover, the wide presence and easy availability of generic drugs for the treatment for actinic keratosis is expected to boost the market growth. However, lack of medical awareness about the skin condition, available treatments, and delayed diagnosis are some of the factors restraining the global actinic keratosis market.

Download PDF Brochure of Research Report: www.coherentmarketinsights.com/insight/request-pdf/1006

Regional segmentation of the actinic keratosis market by Coherent Market Insights comprises North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to dominate the global actinic keratosis market, owing to the presence of abundant treatment options in the region, development of combination therapy in addition to the monotherapy treatment, and sequential actinic keratosis treatment assessed in clinical trials.

According to the National Institute of Health, 2015, actinic keratosis is the second most common diagnosis made by dermatologists with an estimated 5.2 million U.S. population, which visits physician for AK annually, amounting approximately US$ 920 million for the physician visit and treatment. Asia Pacific is expected to witness rapid growth actinic keratosis market, owing to the rapid medical tourism in India and China and the increasing focus of government to improve the healthcare facilities by developing efficacious noninvasive treatment for the condition.

Commitment of major players to develop the effective photodynamic therapy to rise the demand for actinic keratosis treatment

The key players operating the actinic keratosis market are DUSA Pharmaceuticals, Inc., Tolmar Pharmaceuticals, Inc., Perrigo Company plc, Valeant Pharmaceuticals International, Inc., Aqua Pharmaceuticals, LLC, Galderma SA, LEO Laboratories, and Apotex. The major manufacturers are committed to developing innovative products that can effectively manage skin conditions, such as actinic keratosis (AKs).

For instance, actinic keratosis treatment with Levulan Kerastick and BLU-U photodynamic therapy illuminator with blue light illumination introduced by DUSA Pharmaceuticals, Inc. is indicated for the treatment of minimally to moderately thick actinic keratosis of the face or scalp.

Get Request Sample Copy of Research Report: www.coherentmarketinsights.com/insight/request-sample/1006

On the basis of treatment type, the global actinic keratosis treatment market is segmented into:

Topical treatment
5-fluorouracil (5-FU) Cream
Imiquimod Cream
Diclofenac sodium gel
Ingenol mebutate gel
Others
Surgical Procedures
Cryosurgery
Curettage or Scrapping
Electrocautery
Laser Surgery
Others
Photodynamic therapy
On the basis of end user, the actinic keratosis treatment market is segmented into:

Hospitals
Dermatologist Clinics
Oncology Centers
Ambulatory Surgical Centers
Others

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

1001 4th Ave,, #3200, Seattle, WA 98154

This release was published on openPR.